Sanofi $SNY Shares Acquired by Todd Asset Management LLC

Todd Asset Management LLC grew its holdings in Sanofi (NASDAQ:SNY) by 4.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 699,074 shares of the company’s stock after acquiring an additional 29,808 shares during the period. Todd Asset Management LLC’s holdings in Sanofi were worth $32,997,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of SNY. Financial Consulate Inc. acquired a new stake in shares of Sanofi during the third quarter valued at about $26,000. First Horizon Corp purchased a new stake in Sanofi during the 3rd quarter worth approximately $33,000. Salomon & Ludwin LLC boosted its stake in shares of Sanofi by 1,046.3% during the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after buying an additional 701 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of Sanofi by 233.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after buying an additional 700 shares in the last quarter. Finally, Traub Capital Management LLC bought a new stake in shares of Sanofi in the second quarter worth $51,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

More Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Citigroup initiated coverage on shares of Sanofi in a research note on Tuesday, January 27th. They issued a “neutral” rating on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Five analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $62.67.

Sanofi Price Performance

Sanofi stock opened at $46.01 on Monday. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The firm has a market cap of $112.22 billion, a P/E ratio of 12.78, a P/E/G ratio of 1.20 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.29 and a current ratio of 1.09. The business’s fifty day moving average is $47.73 and its two-hundred day moving average is $48.59.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.